A Source for Scientific, Technical and Information Analysis
COLONEL DICK HOOKER, IN MEMORIAM
HOOKER Colonel RICHARD D. HOOKER, SR. (Ret.) Colonel Richard "Dick" Hooker, Sr. passed away on October 24, 2014 at his home in Preston, MD at the age of 80. A native of Pass Christian, Mississippi, Colonel Hooker graduated with Distinguished Honors and an active duty commission from the ROTC program at the University of Mississippi, where he also served as president of the Beta Theta Pi fraternity and editor of the university newspaper.
Colonel Hooker initially served with the 82nd Airborne Division, Fort Bragg, and then with the 8th Division Airborne Brigade in Mainz, Germany. Following the advanced infantry officer course and one year of Vietnamese language training, he began the first of three tours in Vietnam as an advisor to the 2nd Battalion, 8th Regiment, 5th Army of the Republic of Vietnam Division, followed by assignment as aide-de-camp to General William Westmoreland, Commander U.S. Military Assistance Command Vietnam. He then served as an instructor at the Armor School, Fort Knox, before attending Command and General Staff College and then returning to the Republic of Vietnam to serve as G3 Plans Officer, HQ IIFV, Nha Trang, and subsequently assuming command of the 1st Battalion, 50th Infantry (M), then attached to TF South, Phan Thiet. Following five years in the Pentagon with the Army Staff and the Joint Chiefs of Staff, Colonel Hooker was assigned to the U.S. Military Mission to Iran. This tour of duty was followed by assignments as Army attaché to the Philippines, Deputy Chief of the U.S. Military Training Mission in Riyadh, Saudi Arabia, and immediately thereafter as Chief, Office of Military Cooperation, Beirut, Lebanon and Senior U.S. Defense Representative to Lebanon. Colonel Hooker completed his military career in Washington, DC as Special Assistant to the Defense Intelligence Officer for Asia, Defense Intelligence Agency, the Pentagon. He retired from active duty in 1987 after 31 years of service.
His awards and decorations included three awards of the Defense Superior Service Medal, the Legion of Merit, the Bronze Star, eight air medals, various meritorious and commendation medals, and the Lebanese Order of the Cedars, Degree of Commander, Vietnamese Medal of Honor, and Vietnamese Cross of Gallantry. He had also been awarded the Combat Infantry Badge, Master Parachute Badge, Joint Chiefs of Staff Identification Badge, Saudi Arabian Parachute Badge and Philippine Army Parachute Badge. Following his retirement, Colonel Hooker was a consultant, editor and writer, and lived on the Choptank River on Maryland's Eastern Shore.
He was preceded in death by his wife, Bonnie McLemore Hooker, and is survived by three children: Dorothy Hooker Pearce of Newport News, VA, Colonel Richard D. Hooker Jr. of McLean, VA, and MaryAnne Martin of Smithfield, VA; seven grandchildren; and a great-granddaughter.
Interment with full military honors will follow at a later date at Arlington National Cemetery.
In lieu of flowers, the family requests donations be made to the Talbot Hospice Foundation, 586 Cynwood Drive, Easton, Maryland 21601.
Anti-Rejection Drugs for Specialty Drugs: Global Market
Anti-Rejection Drugs for Specialty Drugs: Global Market predicts steady growth for the high-value products through 2018.
Pharmaceutical companies continue to pursue the blockbuster drug that will boost their market shares and profit margins. The companies are identifying which anti-rejection drugs can be adapted across lines of use beyond transplantation and into specialty conditions with potential growth opportunities.
“Novartis is a prime example of a company that has capitalized on the trend,” states Norma Corbitt, a senior analyst with more than 25 years experience in pharmaceutical market research. “Expanding everolimus into oncology has netted the company a blockbuster product, Afinitor/Votubia. The product has also propelled mTOR inhibitors, which had been a relatively small market, to the forefront, passing up antimetabolites in sales and gaining on calcineurin inhibitors.”
The Global Market for Fixed-Dose Combination Drugs
Fixed-dose combination drugs have been used for some time in certain therapeutic categories such as antihypertensives, although they were often reserved for second- or third-line therapy. With the revolution in the survival rates of patients suffering from human immunodeficiency virus (HIV) infection that occurred with the implementation of fixed-drug combination products for this, this delivery technology received a boost of confidence as well as an influx of creative applications to other diseases. For the past several years, a number of fixed-dose combination drugs have been introduced for a variety of diseases, some for the first time in a particular disease category.With this in mind, this STIX Market Research report focuses on the impact of fixed-dose combination drug technology on various therapeutic categories, as well as providing assessments and projections of this technology overall and the impact on the patient compliance and effectiveness.. Specifically the aim of this report is to provide a range of information - from detailed market analyses through industry trends - to quantify and qualify the market for fixed-dose combination drugs for the treatment of selected major diseases. Forecasts and trends are gleaned from industry sources as well as from considered assessment of available and emerging technologies. The report develops forecasts for selected disease categories of the fixed-dose combination drug market from 2012 through 2017 and examines strategies employed by biotechnology companies and pharmaceutical firms to develop and market products in this market sector.
STIX is a consulting and information evaluation organization of experts with experience in advanced technology market analysis and identification of business opportunities. The variety of disciplines in the STIX play book include energy, batteries, fuel cells, advanced materials, nanotechnology, alternative fuels and transportation and membrane technologies.
STIX provides factual evaluations of technologies, profiles of companies in the selected market sector, and advice on acquisitions, transitional business opportunities and due diligence. Start-ups, established companies and government entities will find our services of value.
Copyright 2014 STIX Market Research, All Rights Reserved